FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0295 NP
APPLICATION NO.
10/663,002
APPLICANT
MUKHERJEE ET AL.
FILING DATE
SEPTEMBER 16, 2003
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM						☐	☐
	AN						☐	☐
	AO						☐	☐
	AP						☐	☐
	AQ						☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

JD	AR	Horoszewicz, et al. "LNCaP Model of Human Prostatic Carcinoma", Cancer Res., Vol. 43, pp. 1809-1818 (1983)
JD	AS	Ryan, et al. "HK-2:An immortalized proximal tubule epithelial cell line from normal adult human kidney", Kidney Int'l., Vol. 45, pp 48-57 (1994)
~~JD~~	AT	~~Jiang, et al. "Modulation of cytosolic phospholipase A_2 by PPAR activators in human preadipocytes",~~ J. Lipid Res., Vol. 42, pp. 716-724 (2001) Duplicate Citation

EXAMINER	DATE CONSIDERED
/Jennifer Dunston/ (09/08/2006)	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0295 NP
APPLICATION NO.
10/663,002
APPLICANT
MUKHERJEE ET AL.
FILING DATE
SEPTEMBER 16, 2003
Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

JD	2AA	Mukherjee, et al. "Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor α", J. of Steroid Biochem & Mol. Biol., Vol. 81, pp. 217-225 (2002)
	2AB	Kliewer, et al. "Peroxisome Proliferator-Activated Receptors:From Genes to Physiology", Endocrine Society, pp. 239-263 (2001)
	2AC	Xu, et al. "Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors", PNAS, Vol. 98, No. 24, pp. 13919-13924 (2001)
	2AD	Kliewer, et al. "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ", Proc. Natl. Acad. of Sci., Vol. 94, pp. 4318-4323 (1997)
	2AE	Forman, et al. "Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ", Proc. Natl. Acad. Sci., Vol. 94, pp. 4312-4317 (1997)
	2AF	Hsu, et al. "Identification of Peroxisome Proliferator-responsive Human Genes by Elevated Expression of the Peroxisome Proliferator- activated Receptor α inHepG2 Cells", J. of Biolog. Chem., Vol. 276, pp. 27950-27958 (2001)
	2AG	Lawrence, et al. "Differential Gene Regulation in Human *versus* Rodent Hepatocytes by Peroxisome Proliferator-activated Receptor (PPAR) α", J. of Biol. Chem., Vol. 276, No. 34, pp. 31521-31527 (2001)
	2AH	Mukherjee, et al. "Human and Rat Peroxisome Proliferator Activated Receptors (PPARs) Demonstrate Similar Tissue Distribution but Different Responsiveness to PPAR Activators, J. Steroid Biochem. Molec. Biol., Vol. 51, No. 3/4, pp. 157-166 (1994)
	2AI	Holness, et al. "Targeted Upregulation of Pyruvate Dehydrogenase Kinase (PDK)-4 in Slow-Twitch Skeletal Muscle Underlies the Stable Modification of the Regulatory Characteristics of PDK Induced by High-Fat Feeding", Diabetes, Vol. 49, pp. 775-781 (2000)
	2AJ	Huang, et al. "Regulation of Pyruvate Dehydrogenase Kinase Expression by Peroxisome Proliferator-Activated Receptor-α Ligands, Glucocorticoids, and Insulin", Diabetes, Vol. 51, pp. 276-283 (2002)
	2AK	Willson, et al. "The PPARs:From Orphan Receptors to Drug Discovery", J. of Med. Chem., Vol. 43, No. 4, pp. 527-550 (2000)
	2AL	Wu, et al. "Mechanism Responsible for Inactivation of Skeletal Muscle Pyruvate Dehydrogenase Complex in Starvation and Diabetes", Diabetes, Vol. 48, pp. 1593-1599 (1999)
	2AM	Sugden, et al. "Role of Peroxisome-Activated Receptor-α in the Mechanism Underlying Changes in Renal Pyruvate Dehydrogenase Kinase Isoform 4 Protein Expression in Starvation and after Refeeding", Biochem. and Biophysics, Vol. 395, No. 2, pp. 246-252 (2001)
JD	2AN	Wu, et al. "Adaptive Increase in Pyruvate Dehydrogenase Kinase 4 during Starvation is Mediated by Peroxisome Proliferator-Activated Receptor α", Biochem and Biophysical Res. Comm., Vol. 287, pp. 391-396 (2001)

EXAMINER	DATE CONSIDERED
/Jennifer Dunston/ (09/08/2006)	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0295 NP
APPLICATION NO.
10/663,002
APPLICANT
MUKHERJEE ET AL.
FILING DATE
SEPTEMBER 16, 2003
Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

JD	3AA	Wu, et al. "Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart", Biochem. J., Vol. 329, pp. 197-201 (1998)
~~JD~~	3AB	Way, et al. "Comprehensive Messenger Ribonucleic Acid Profiling Reveals That ~~Peroxisome Proliferator-Activated Receptor γ~~ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues", Endocrinology, Vol. 142, No. 3, pp. 1269-1277 (2001) Duplicate Citation
JD	3AC	Mukherjee, et al. "Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPARγ2 *versus* PPARγ1 and Activation with Retinoid X Receptor Agonists and Antagonists", J. of Biol. Chem., Vol. 272, No. 12, pp. 8071-8076
JD	3AD	Brown, et al. "A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering Activity", J. Med. Chem., Vol. 42, pp. 3785-3788 (1999)
	AE	
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER	DATE CONSIDERED
/Jennifer Dunston/ (09/08/2006)	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
D0295 NP
APPLICATION NO.
10/663,002
APPLICANT
MUKHERJEE ET AL.
FILING DATE
SEPTEMBER 16, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM						☐	☐
	AN						☐	☐
	AO						☐	☐
	AP						☐	☐
	AQ						☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

JD	AR	Aljada, et al., "Troglitazone Reduces the Expression of PPARγ While Stimulating That of PPARα in Mononuclear Cells in Obese Subjects", J. Clin. Endocrin. Metab., Vol. 86(7), pp. 3130-3131 (2001)
JD	AS	Kersten, et al., "Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting", J. Clin. Invest., Vol. 103(11), pp. 1489-1498 (1999)
JD	AT	Xu, et al., "Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα", Nature, Vol. 415, pp. 813-817 (2002)

EXAMINER	DATE CONSIDERED
/Jennifer Dunston/ (09/08/2006)	

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.